According to a new report published by Introspective Market Research, titled, Smart Insulin Pens Market by Product Type, Indication, and End User, The Global Smart Insulin Pens Market Size Was Valued at USD 1.03 Billion in 2024 and is Projected to Reach USD 3.45 Billion by 2035, Growing at a CAGR of 12.86% from 2025–2035.
The smart insulin pens market is gaining strong momentum as diabetes management increasingly shifts toward connected, data-driven, and patient-centric solutions. Smart insulin pens are advanced drug-delivery devices that combine traditional insulin pens with digital technologies such as dose tracking, memory functions, Bluetooth connectivity, and mobile app integration. These features help patients and healthcare providers monitor insulin usage more accurately, reduce dosing errors, and improve overall glycemic control.
Compared to conventional insulin pens and syringes, smart insulin pens offer significant advantages, including real-time dose logging, reminders, and integration with continuous glucose monitoring (CGM) systems. These capabilities enhance treatment adherence and support personalized diabetes care. Smart insulin pens are widely used in the management of type 1 and type 2 diabetes across hospitals, specialty clinics, and home-care settings, supporting both basal and bolus insulin therapies.
Market Segmentation
The Smart Insulin Pens Market is segmented into Product Type, Indication, and End User.
- By Product Type, the market is categorized into First-Generation Smart Insulin Pens, Second-Generation Smart Insulin Pens, and Connected Pen Caps.
- By Indication, the market is categorized into Type 1 Diabetes, Type 2 Diabetes, and Gestational Diabetes.
- By End User, the market is categorized into Hospitals, Clinics, and Home Care Settings.
Growth Driver
One of the key growth drivers for the smart insulin pens market is the rapidly increasing global prevalence of diabetes. Rising sedentary lifestyles, unhealthy dietary habits, and an aging population have significantly increased the number of patients requiring long-term insulin therapy. Smart insulin pens address critical challenges associated with diabetes management, such as missed doses and incorrect insulin administration. By enabling automated dose tracking and digital monitoring, these devices improve treatment outcomes and reduce diabetes-related complications, thereby driving their adoption among patients and healthcare providers worldwide.
Market Opportunity
A major market opportunity lies in the integration of smart insulin pens with digital health ecosystems, including mobile health apps, cloud-based platforms, and telemedicine services. As healthcare systems increasingly adopt remote patient monitoring and personalized medicine, smart insulin pens can play a central role in data-driven diabetes care. Emerging markets also present strong growth potential due to improving healthcare infrastructure, rising awareness of advanced diabetes management tools, and increasing smartphone penetration, which supports connected device adoption.
Detailed Segmentation
Smart Insulin Pens Market, Segmentation
The Smart Insulin Pens Market is segmented on the basis of Product Type, Indication, and End User.
Product Type
The Product Type segment is further classified into First-Generation Smart Insulin Pens, Second-Generation Smart Insulin Pens, and Connected Pen Caps. Among these, the Second-Generation Smart Insulin Pens sub-segment accounted for the highest market share in 2024. These devices offer enhanced connectivity, advanced analytics, and seamless integration with CGM systems and smartphones. Their ability to provide real-time insights, dosing recommendations, and improved user experience has accelerated adoption among both patients and clinicians.
Indication
The Indication segment is further classified into Type 1 Diabetes, Type 2 Diabetes, and Gestational Diabetes. Among these, the Type 2 Diabetes sub-segment accounted for the highest market share in 2024. The large patient population requiring insulin therapy, combined with the growing focus on improving adherence and long-term disease management, has driven strong demand for smart insulin pens in type 2 diabetes care.
Some of The Leading/Active Market Players Are-
• Novo Nordisk A/S (Denmark)
• Eli Lilly and Company (USA)
• Sanofi S.A. (France)
• Medtronic plc (Ireland)
• Companion Medical (USA)
• Bigfoot Biomedical (USA)
• Emperra GmbH E-Health Technologies (Germany)
• Ypsomed Holding AG (Switzerland)
• Diamesco Co., Ltd. (South Korea)
• Owen Mumford Ltd. (UK)
• Biocorp Production (France)
• Roche Holding AG (Switzerland)
• Abbott Laboratories (USA)
• Dexcom, Inc. (USA)
• Insulet Corporation (USA)
and other active players.
Key Industry Developments
In March 2024, Novo Nordisk announced the expansion of its smart insulin pen portfolio with enhanced digital connectivity features.
The update focuses on improved data accuracy, better integration with diabetes management platforms, and enhanced patient engagement, supporting personalized insulin therapy and improved clinical outcomes.
In September 2024, Medtronic collaborated with a digital health company to integrate smart insulin pen data with advanced diabetes management software.
This development aims to enable seamless data sharing between patients and healthcare providers, strengthening remote monitoring capabilities and supporting data-driven treatment decisions.
Key Findings of the Study
• Second-generation smart insulin pens dominate the market due to advanced connectivity features
• Type 2 diabetes represents the leading indication segment globally
• North America holds a significant market share, followed by Europe
• Rising diabetes prevalence is a primary growth driver
• Digital integration and remote monitoring are key market trends
